uniQure (QURE) Competitors $15.38 +1.13 (+7.93%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$15.45 +0.07 (+0.46%) As of 06:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. HCM, IMVT, KYMR, CRNX, MOR, ALVO, RXRX, MIRM, CPRX, and NAMSShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include HUTCHMED (HCM), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors HUTCHMED Immunovant Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Recursion Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals NewAmsterdam Pharma HUTCHMED (NASDAQ:HCM) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Do analysts recommend HCM or QURE? HUTCHMED currently has a consensus price target of $23.50, indicating a potential upside of 33.75%. uniQure has a consensus price target of $37.82, indicating a potential upside of 145.89%. Given uniQure's stronger consensus rating and higher possible upside, analysts plainly believe uniQure is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91 Which has better earnings and valuation, HCM or QURE? HUTCHMED has higher revenue and earnings than uniQure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M4.86$37.73MN/AN/AuniQure$27.12M31.07-$239.56M-$4.39-3.50 Is HCM or QURE more profitable? HUTCHMED has a net margin of 0.00% compared to uniQure's net margin of -1,077.05%. HUTCHMED's return on equity of 0.00% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A uniQure -1,077.05%-483.87%-34.28% Do institutionals & insiders have more ownership in HCM or QURE? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, HCM or QURE? HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Does the media refer more to HCM or QURE? In the previous week, HUTCHMED had 1 more articles in the media than uniQure. MarketBeat recorded 2 mentions for HUTCHMED and 1 mentions for uniQure. HUTCHMED's average media sentiment score of 0.80 beat uniQure's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHUTCHMED beats uniQure on 8 of the 15 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$780.55M$2.99B$5.57B$9.42BDividend YieldN/A2.44%4.05%3.99%P/E Ratio-3.5021.2528.1520.08Price / Sales31.07253.33401.6884.07Price / CashN/A41.9636.1958.45Price / Book-109.868.198.625.83Net Income-$239.56M-$55.10M$3.24B$258.27M7 Day Performance1.18%5.56%3.55%2.69%1 Month Performance8.16%18.19%11.01%12.91%1 Year Performance90.35%7.32%35.56%21.81% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure1.8383 of 5 stars$15.38+7.9%$37.82+145.9%+91.4%$780.55M$27.12M-3.50500Upcoming EarningsHCMHUTCHMED2.8054 of 5 stars$17.74+0.9%$19.00+7.1%-7.0%$3.09B$630.20M0.001,811Positive NewsAnalyst ForecastIMVTImmunovant1.0993 of 5 stars$17.70-1.2%$36.30+105.1%-34.3%$3.03BN/A-6.46120Positive NewsKYMRKymera Therapeutics3.1757 of 5 stars$45.14-2.3%$59.11+31.0%+6.8%$2.94B$47.07M-14.56170CRNXCrinetics Pharmaceuticals3.6067 of 5 stars$30.95-0.5%$69.50+124.6%-43.5%$2.90B$1.04M-8.10210MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.8787 of 5 stars$8.64+0.1%$16.00+85.2%-22.4%$2.60B$491.98M23.351,032RXRXRecursion Pharmaceuticals0.9099 of 5 stars$6.40+9.6%$7.00+9.4%-25.1%$2.60B$58.84M-3.62400Analyst RevisionGap UpHigh Trading VolumeMIRMMirum Pharmaceuticals3.4069 of 5 stars$51.95+0.0%$65.50+26.1%+32.0%$2.57B$336.89M-32.27140CPRXCatalyst Pharmaceuticals4.9216 of 5 stars$21.01-0.1%$32.83+56.3%+22.8%$2.56B$491.73M13.3880Positive NewsNAMSNewAmsterdam Pharma3.6354 of 5 stars$22.56+1.6%$41.30+83.1%+26.6%$2.53B$45.56M-12.004 Related Companies and Tools Related Companies HCM Alternatives IMVT Alternatives KYMR Alternatives CRNX Alternatives MOR Alternatives ALVO Alternatives RXRX Alternatives MIRM Alternatives CPRX Alternatives NAMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
